• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个临床有效的乳腺癌筛查项目也可以具有成本效益。

A clinically effective breast cancer screening program can be cost-effective, too.

作者信息

Carter A P, Thompson R S, Bourdeau R V, Andenes J, Mustin H, Straley H

出版信息

Prev Med. 1987 Jan;16(1):19-34. doi: 10.1016/0091-7435(87)90003-x.

DOI:10.1016/0091-7435(87)90003-x
PMID:3103118
Abstract

The logistics of complying with current American Cancer Society breast cancer screening recommendations in a large health maintenance organization, serving more than 50,000 women age 40 or older, are described. An alternative screening approach estimated to be at least as health-effective as the American Cancer Society recommendations has been developed and appears to solve the problem and is financially feasible. Cost-effectiveness depends on optimal use of mammography and health-care personnel resources. The authors show how the start-up and maintenance costs of an organized program can be offset by future cost savings resulting from reduced long-term disability in patients diagnosed at Stages 0-1 as opposed to Stages 2 and later. Careful selection of the delivery model before implementation can make a breast cancer screening program cost-effective as well as health-effective.

摘要

本文描述了一家为超过5万名40岁及以上女性提供服务的大型健康维护组织中,遵循美国癌症协会乳腺癌筛查建议的后勤工作。已开发出一种替代筛查方法,估计其健康效果至少与美国癌症协会的建议相同,该方法似乎解决了问题且在财务上可行。成本效益取决于乳房X光检查和医疗保健人员资源的最佳利用。作者表明,与2期及更晚期诊断的患者相比,0-1期诊断的患者长期残疾减少,由此带来的未来成本节省可以抵消有组织项目的启动和维护成本。在实施前仔细选择交付模式,可以使乳腺癌筛查项目既具有成本效益又具有健康效益。

相似文献

1
A clinically effective breast cancer screening program can be cost-effective, too.一个临床有效的乳腺癌筛查项目也可以具有成本效益。
Prev Med. 1987 Jan;16(1):19-34. doi: 10.1016/0091-7435(87)90003-x.
2
Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.发展中国家的乳腺癌筛查政策:印度的成本效益分析
J Natl Cancer Inst. 2008 Sep 17;100(18):1290-300. doi: 10.1093/jnci/djn292. Epub 2008 Sep 9.
3
The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.奥地利乳腺癌组织性筛查与机会性筛查的长期有效性及成本效益
Value Health. 2017 Sep;20(8):1048-1057. doi: 10.1016/j.jval.2017.04.009. Epub 2017 May 16.
4
Retrospective cost-effectiveness analysis of screening mammography.乳腺钼靶筛查的回顾性成本效益分析。
J Natl Cancer Inst. 2006 Jun 7;98(11):774-82. doi: 10.1093/jnci/djj210.
5
Cost-effective management of breast cancer.乳腺癌的经济高效管理。
Cancer. 1992 Apr 1;69(7 Suppl):1979-84. doi: 10.1002/1097-0142(19920401)69:7+<1979::aid-cncr2820691719>3.0.co;2-c.
6
7
[Economic approach to breast cancer screening in Belgium].[比利时乳腺癌筛查的经济学方法]
Rev Med Brux. 1995 Jul-Aug;16(4):326-9.
8
Program-specific cost-effectiveness analysis: breast cancer screening policies for a safety-net program.特定项目成本效益分析:为一个安全网项目制定的乳腺癌筛查政策。
Value Health. 2013 Sep-Oct;16(6):932-41. doi: 10.1016/j.jval.2013.06.013.
9
Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening.乳腺钼靶摄影、磁共振成像及超声检查用于乳腺癌筛查的成本效益
Radiol Clin North Am. 2010 Sep;48(5):879-91. doi: 10.1016/j.rcl.2010.06.002.
10
[Cost-effectiveness analysis of two breast cancer screening modalities in Shanghai, China].[中国上海两种乳腺癌筛查方式的成本效益分析]
Zhonghua Zhong Liu Za Zhi. 2015 Dec;37(12):944-51.

引用本文的文献

1
Breast cancer screening outreach effectiveness: Mammogram-specific reminders vs. comprehensive preventive services birthday letters.乳腺癌筛查外展效果:乳腺 X 光具体提醒与综合预防服务生日信。
Prev Med. 2017 Sep;102:49-58. doi: 10.1016/j.ypmed.2017.06.028. Epub 2017 Jun 24.
2
Does litigation influence medical practice? The influence of community radiologists' medical malpractice perceptions and experience on screening mammography.诉讼会影响医疗行为吗?社区放射科医生的医疗事故认知和经验对乳腺钼靶筛查的影响。
Radiology. 2005 Jul;236(1):37-46. doi: 10.1148/radiol.2361040512.
3
Mammographers' perception of women's breast cancer risk.
乳腺造影技师对女性乳腺癌风险的认知。
Med Decis Making. 2005 May-Jun;25(3):283-9. doi: 10.1177/0272989X05276857.
4
Current realities of delivering mammography services in the community: do challenges with staffing and scheduling exist?社区乳腺钼靶检查服务的当前现状:人员配备和排班方面是否存在挑战?
Radiology. 2005 May;235(2):391-5. doi: 10.1148/radiol.2352040132. Epub 2005 Mar 29.
5
The association between obesity and screening mammography accuracy.肥胖与乳腺钼靶筛查准确性之间的关联。
Arch Intern Med. 2004 May 24;164(10):1140-7. doi: 10.1001/archinte.164.10.1140.
6
Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.他莫昔芬:关于其作为乳腺癌女性辅助治疗药物的药物经济学及生活质量考量的综述
Pharmacoeconomics. 1993 Jul;4(1):40-66. doi: 10.2165/00019053-199304010-00006.
7
Using physician correspondence and postcard reminders to promote mammography use.利用医生信函和明信片提醒来促进乳房X光检查的使用。
Am J Public Health. 1994 Apr;84(4):571-4. doi: 10.2105/ajph.84.4.571.
8
Assessing prevention effectiveness using data to drive program decisions.利用数据评估预防效果,以推动项目决策。
Public Health Rep. 1994 Mar-Apr;109(2):187-94.
9
The danger of applying uniform clinical policies across populations: the case of breast cancer in American Indians.对不同人群应用统一临床政策的风险:以美国印第安人的乳腺癌为例。
Am J Public Health. 1994 Oct;84(10):1631-6. doi: 10.2105/ajph.84.10.1631.
10
Breast cancer risk and participation in mammographic screening.乳腺癌风险与乳腺钼靶筛查参与情况
Am J Public Health. 1989 Nov;79(11):1494-8. doi: 10.2105/ajph.79.11.1494.